{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:43:24Z","timestamp":1779252204551,"version":"3.51.4"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We present a case of Pseudomonas aeruginosa osteomyelitis treated with surgery and antibiotic therapy with ceftolozane-tazobactam in continuous infusion at home using an elastomeric pump. We discuss the use of ceftolozane-tazobactam in continuous infusion administered at home as an effective alternative for the treatment of multidrug-resistant Pseudomonas aeruginosa osteomyelitis.<\/jats:p>","DOI":"10.1093\/ofid\/ofaa409","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T07:44:16Z","timestamp":1600155856000},"source":"Crossref","is-referenced-by-count":12,"title":["Outpatient Parenteral Antimicrobial Therapy With Ceftolozane\/Tazobactam via Continuous Infusion for Multidrug-Resistant Pseudomonas aeruginosa Osteomyelitis"],"prefix":"10.1093","volume":"7","author":[{"given":"Judith","family":"\u00c1lvarez Otero","sequence":"first","affiliation":[{"name":"Internal Medicine (Infectious Diseases Division), Povisa Hospital, Vigo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Lamas Ferreiro","sequence":"additional","affiliation":[{"name":"Internal Medicine (Infectious Diseases Division), Povisa Hospital, Vigo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Sanjurjo Rivo","sequence":"additional","affiliation":[{"name":"Internal Medicine (Infectious Diseases Division), Povisa Hospital, Vigo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"de la Fuente Aguado","sequence":"additional","affiliation":[{"name":"Internal Medicine, Povisa Hospital, Vigo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,9,15]]},"reference":[{"key":"2020110908121847000_CIT0001","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofaa014","article-title":"Clinical and safety evaluation of continuously infused ceftolozane\/tazobactam in the outpatient setting","volume":"7","author":"Jones","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2020110908121847000_CIT0002","author":"National Healthcare Safety Network."},{"key":"2020110908121847000_CIT0003","author":"Europe Center for Disease Prevention and Control."},{"key":"2020110908121847000_CIT0004","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020110908121847000_CIT0005","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"2020110908121847000_CIT0006","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2020110908121847000_CIT0007","doi-asserted-by":"crossref","first-page":"2042098619862083","DOI":"10.1177\/2042098619862083","article-title":"Ceftolozane-tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series","volume":"11","author":"Tan","year":"2019","journal-title":"Ther Adv Drug Saf"},{"key":"2020110908121847000_CIT0008","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ijantimicag.2017.11.003","article-title":"Ceftolozane\/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes","volume":"51","author":"Dietl","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2020110908121847000_CIT0009","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1093\/jac\/dkx172","article-title":"Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane\/tazobactam monotherapy","volume":"72","author":"Gentile","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020110908121847000_CIT0010","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-217005","article-title":"Successful treatment of multidrug-resistant Pseudomonas aeruginosa pubic symphysis osteomyelitis with ceftolozane\/tazobactam","author":"Kurtzhalts","year":"2017","journal-title":"BMJ Case Rep"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa409\/33747918\/ofaa409.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/11\/ofaa409\/34176443\/ofaa409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/11\/ofaa409\/34176443\/ofaa409.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T13:43:58Z","timestamp":1604929438000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa409\/5905720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa409","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,9,15]]},"article-number":"ofaa409"}}